Background Until now there has been scarce evidence regarding an optimal antiplatelet strategy and clinical outcomes for patients who had suffered from stent thrombosis (ST). Methods and Results 140 patients who suffered from stent thrombosis were prospectively registered. Patients received dual (aspirin and 150 mg clopidogrel, N = 66) or triple (additional cilostazol, N = 74) antiplatelet therapy at the physician’s discretion. Thereafter platelet reactivity and one year clinical outcomes were analyzed. The primary outcome included the composite of cardiac death, non-fatal myocardial infarction (MI) or stroke at one year,which developed in 41 (29.3%) patients, consisting of 31 (22.1%) cardiac death, 9 (6.4%) non-fatal MI and 1 (1.4%) stroke. Recurrent definite and probable ST according to ARC definition was observed in 8 (5.7%) and 14 (10.0%) patients, respectively. Triple therapy was associated with significantly lower platelet reactivities (50.2±17.8, % vs. 59.6±17.2, %, P = 0.002) compared to high dose dual antiplatelet therapy. However, the incidence of primary events (24.3% vs. 34.8%, P = 0.172) did not differ between triple and dual antiplatelet therapies. High on-treatment platelet reactivity (HR: 8.35, 95% CI: 2.234~30.867, P = 0.002) and diabetes (HR: 3.732, 95% CI: 1.353~10.298, P = 0.011) were independent predictors of primary events. Conclusions Patients who suffered from stent thrombosis have a poor prognosis even after revascularization with intensive antiplatelet therapy. Triple antiplatelet therapy was more effective in reducing on-treatment platelet reactivity, compared to high dose dual antiplatelet therapy.
References
[1]
Cutlip DE, Baim DS, Ho KK, Popma JJ, Lansky AJ, et al. (2001) Stent thrombosis in the modernera: a pooled analysis of multicenter coronary stent clinical trials. Circulation 103: 1967–1971.
[2]
Orford JL, Lennon R, Melby S, Fasseas P, Bell MR, et al. (2002) Frequency and correlates of coronary stent thrombosis in the modern era: analysis of a single center registry. J Am Coll Cardiol 40: 1567–1572.
[3]
Takayama T, Hiro T, Hirayama A (2011) Stent thrombosis and drug-eluting stents. J Cardiol 58: 92–98.
[4]
Han Y, Li Y, Wang S, Jing Q, Wang Z, et al. (2009) Cilostazol in addition to aspirin and clopidogrel improves long-term outcomes after percutaneous coronary intervention in patients with acute coronary syndromes: a randomized, controlled study. Am Heart J 157: 733–739.
[5]
Chen KY, Rha SW, Li YJ, Poddar KL, Jin Z, et al. (2009) Triple versus dual antiplatelet therapy in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Circulation 119: 3207–3214.
[6]
Fei Gao, Yu Jie Zhou, Zhi Jian Wang, Hua Shen, Xiao Li Liu, et al. (2010) Comparison of Different Antithrombotic Regimens for Patients With Atrial Fibrillation Undergoing Drug-Eluting Stent Implantation. Circulation Journal 74: 701–708.
[7]
Ryan TJ, Faxon DP, Gunnar RM, Kennedy JW, King SB 3rd, et al (1988) Guidelines for percutaneous transluminal coronary angioplasty. A report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Subcommittee on Percutaneous Transluminal Coronary Angioplasty). J Am Coll Cardiol 12: 529–545.
[8]
Ong AT, Hoye A, Aoki J, van Mieghem CA, Rodriguez Granillo GA, et al. (2005) Thirty-day incidence and 6-month clinical outcome of thrombotic stent occlusion after bare-metal, sirolimus, or paclitaxel stent implantation. J Am Coll Cardiol 45: 947–953.
[9]
Rao AK, Pratt C, Berke A, Jaffe A, Ockene I, et al. (1988) Thrombolysis In Myocardial Infarction (TIMI) Trial. Phase I: Hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol 1988 11: 1–11.
[10]
Li Y, Li CX, Wang HC, Xu B, Fang WY, et al. (2011) Efficacy and safety of Firebird sirolimus-eluting stent in treatment of complex coronary lesions in Chinese patients: one-year clinical and eight-month angiographic outcomes from the FIREMAN registry. Chin Med J (Engl) 124: 817–824.
[11]
Garg S, Serruys PW, Silber S, Wykrzykowska J, van Geuns RJ, et al. (2011) The prognostic utility of the SYNTAX score on 1-year outcomes after revascularization with zotarolimus- and everolimus-eluting stents: a substudy of the RESOLUTE All Comers Trial. JACC Cardiovasc Interv 4: 432–441.
[12]
Geisler T, Grass D, Bigalke B, Stellos K, Drosch T, et al. (2008) The Residual Platelet Aggregation after Deployment of Intracoronary Stent (PREDICT) score. J Thromb Haemost 6: 54–61.
[13]
Elsenberg EH, van Werkum JW, van de Wal RM, Zomer AC, Bouman HJ, et al. (2009) The influence of clinical characteristics, laboratory and inflammatory markers on ‘high on treatment platelet reactivity’ asmeasured with different platelet function tests. Thromb Haemost 102: 719–727.
[14]
Kereiakes DJ, Choo JK, Young JJ, Broderick TM (2004) Thrombosis and drug-eluting stents: a critical appraisal. Rev Cardiovasc Med 5: 9–15.
[15]
Popovic B, Casu AG, Angioi M, Moulin F, Piquemal R, et al. (2005) Acute or sub-acute thrombosis of steel stents. Arch Mal Coeur Vaiss 98: 1187–1191.
[16]
Lemesle G, Delhaye C, Bonello L, de Labriolle A, Waksman R, et al. (2008) Stent thrombosis in 2008: definition, predictors, prognosis and treatment. Arch Cardiovasc Dis 101: 769–777.
[17]
Trabattoni D, Fabbiocchi F, Montorsi P, Ravagnani P, Galli S, et al. (2007) Stent thrombosis after sirolimus- and paclitaxel-eluting stent implantation in daily clinical practice: analysis of a single center registry. Catheter Cardiovasc Interv 70: 415–421.
[18]
Yeo KK, Mahmud E, Armstrong EJ, Bennett WE, Shunk KA, et al.. (2011) Contemporary clinical characteristics, treatment, and outcomes of angiographically confirmed coronary stent thrombosis: Results from a multicenter California registry. Catheter Cardiovasc Interv. In press.
[19]
Gurbel PA, Bliden KP, Samara W, Yoho JA, Hayes K, et al. (2005) Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST study. J Am Coll Cardiol 46: 1827–1832.
[20]
Davì G, Vazzana N, Sestili S. (2012) Variability in the response to antiplatelet treatment in diabetes mellitus. Prostaglandins Other Lipid Mediat. In press.
[21]
Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, et al. (2005) Incidence, predictors, and outcome of thrombosis after successful implantation of drug eluting stents. JAMA 293: 2126–2130.
[22]
Pramod K, Kuchulakanti, Chu WW, Ohlmann P, Rha SW, et al. (2006) Correlates and Long-term outcomes of angiographically proven stent thrombosis with sirolimus- and paclitaxel-eluting stents. Circulation 113: 1108–1113.
[23]
Breet NJ, van Werkum JW, Bouman HJ, Kelder JC, Ruven HJ, et al. (2010) Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA 303: 754–762.
[24]
Shaw JA, Andrianopoulos N, Duffy S, Walton AS, Clark D, et al. (2008) Renal impairment is an independent predictor of adverse events post coronary intervention in patients with and without drug-eluting stents. Cardiovasc Revasc Med 9: 218–223.
[25]
Stein B, Weintraub WS, Gebhart SP, Cohen-Bernstein CL, Grosswald R, et al. (1995) Influence of diabetes mellitus on early and late outcome after percutaneous transluminal coronary angioplasty. Circulation 91: 979–989.
[26]
Siller-Matula JM, Delle-Karth G, Christ G, Neunteufl T, Maurer G, et al..(2012) Dual non-responsiveness to antiplatelet treatment is a stronger predictor of cardiac adverse events than isolated non-responsiveness to clopidogrel or aspirin. Int J Cardiol. In press.
[27]
van Werkum JW, Heestermans AA, Zomer AC, Kelder JC, Suttorp MJ, et al. (2009) Predictors of coronary stent thrombosis. J Am Coll Cardiol 53: 1399–1409.
[28]
Lee SW, Park SW, Yun SC, Kim YH, Park DW, et al. (2010) Triple antiplatelet therapy reduces ischemic events after drug-eluting stent implantation: Drug-Eluting stenting followed by Cilostazol treatment REduces Adverse Serious cardiac Events (DECREASE registry). Am Heart J 159: 284–291.
